US-NJ, Executive Director, Early Commercial Strategy - Immuno Oncology 225124BR-MZ
Executive Director, Early Commercial Strategy - Immuno Oncology
East Hanover, NJ
The Executive Director, Immuno-oncology (IO) Early Commercial Strategy, is a key leadership position with global responsibility to advocate for development strategies and pre-launch activities to enable Novartis Oncology to realize our aspirations to lead in the second wave of IO therapeutics.
The Executive Director, Immuno-oncology Early Commercial Strategy, leads a small team responsible to ensure the commercial relevance and competitive success of a complex portfolio of more than 24+ pipeline IO assets. The high complexity of this global position is reflected by several aspects. First, given the broad therapeutic relevance of IO, the Executive Director must be able to cover all major tumor types, as well as some smaller ones, which might provide an opportunity to Novartis as a later entrant in IO. Second, given this broad therapeutic relevance of IO necessitates a very broad set of interactions, within Novartis Oncology, Oncology Global Development Unit, NIBR s IO Unit and Translational Clinical Oncology as well as externally. Third, as the IO space is characterized by unprecedented R&D investment, competitive intensity and rapidly evolving data, the Executive Director needs to cultivate and maintain a center of excellence cognizant of not only the IO trends and news, but also their implications to Novartis Oncology.
1)Provides leadership on the complex and diverse pipeline of IO assets, working with key stakeholders at the global level, including the VP, Early Commercial Strategy, Senior VP, BD&L and Strategy, Senior VP, Global Marketing and Access, Global Head, Translational Clinical Oncology, Global Head, Exploratory Immuno-Oncology, and multipIe Senior VP Global Program Heads.
2)Manages 2-3 directors/senior directors who each provide commercial strategy and inputs into multiple individual IO pipeline asset programs, by driving an integrated and collaborative process with numerous stakeholders including Global Marketing, Global Value & Access, Regional commercial heads, TCO, NIBR, and external consultants.
3)Early Commercial Strategy member of leadership team for the Solid Tumors Franchise Leadership Team (FLT), where many of the early pipeline assets are being tested, in order to advocate for opportunities to advance IO pipeline assets in differentiated ways. Solid tumor FLT leadership stakeholders include two Senior VP Global Program Heads and multiple VP Global Disease Leads. Provide insights on external environment, including competitive landscape, payer/reimbursement requirements, unmet medical needs, and evolving treatment patterns.
4)Early Commercial Strategy representative to the PDR001 Center of Excellence, which is the key coordinating body for PDR001-based full development programs. (PDR001 is the cur-rent and projected future backbone of our IO combinations.) Key stakeholders on the PDR001 Center of Excellence are the Sr VP of Lung and Liver Cancer and VP level members of the Global Value and Access team and Global Medical Affairs.
5)Assess commercial potential of early development programs and provide feedback on development decisions to optimize competitiveness and commercial success of assets. Develop commercial forecasts; work with other Early Commercial Strategy and VP level Global Disease Leads from Global Marketing to coordinate and collaborate on development of pipeline assets for patients with same tumor types. Key stakeholders include Global Marketing colleagues as well as Global Finance.
6)Drive external messaging about the IO pipeline assets. Key stakeholders include senior leaders in the global Oncology Medical Affairs as well as senior leaders of Translational Clinical Oncology. Key activities are: (a) collaborate with Scientific Communications colleagues to support IO asset publication planning; (b) supervise development of educational tools for external audiences (e.g., compound cards, MOA summaries) and internal constituencies; (c) oversee IO asset generic name development and support clinical trial naming/branding activities; (d) supervise development of initiatives to support clinical trial enrollment.
7)IO lead for Global Business Development & Licensing Commercial Support. Assess external assets for commercial potential; prepare top-line forecasts. This involves working with key stakeholders in the Oncology BD&L team, including the VP of Oncology BD&L, the VP of BD&L Finance and various Senior VP Global Program Heads from GDD. Specific actions include: (a) work closely with BD&L colleagues and associated team members to develop and iteratively refine commercial assessments commensurate with the level of data available; (b) determine current payer environment and propose likely pricing strategy; (c) prepare and present Novartis Oncology s commercial capabilities to potential partners; (d) identify synergies with in-house pipeline; (e) advise on optimal commercial deal structure; review collaboration contracts.
8)Advance commercial considerations of IO biomarker identification and associated IO companion diagnostic development. This involves engaging key stakeholders from the Oncolo-gy Precision Medicine (OPM), including the Sr VP Global Head of OPM, various other VPs within OPM and Global Head, Oncology Translational Research in NIBR.
9)Provide commercial feedback to technical development colleagues to impact formulation and packaging development decisions.
The Novartis Group of Companies are Equal Opportunity Employers and take pride in maintaining a diverse environment. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status.
University degree in Marketing, Medicine, Natural or Pharmaceutical Sciences.
An advanced degree in science and/or business preferred (e.g., MD, Pharm. D., PhD., MBA)
Fluency in English
At least 8-10 years of healthcare strategic and/or operational marketing / product management or related experience oncology preferred
Understanding of the drug development process, especially regarding opportunities for differentiation and value demonstration
Comfortable rapidly switching between complex science and commercial concepts, with an ability to bridge between them and build common understanding amongst people on either side
Experience managing complex projects and diverse project teams to achieve goals on time
Superior analytical and quantitative skills; competence with Excel.
Strong communications skills, written, verbal and presentation.
Compound evaluation experience
Ability to work with Oncology/Hematology Medical experts
Proven ability to collaborate, operate and influence cross-functionally and cross-culturally
Proven leadership ability, with strong analytical, strategic thinking and project management skills
* If a direct employer requests that you go to their web site and complete your application there in order to be
considered, please do so. Applications for all positions are subject to each employer's specific requirements.